Vertex, Mammoth Launch Up-to-$695M CRISPR Gene-Editing Collaboration
Vertex Pharmaceuticals will develop in vivo gene-editing therapies for two genetic diseases using Mammoth Biosciences’ CRISPR systems through a collaboration that could generate more than $695 million for Mammoth.
Source: genengnews.com